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Abstract
Background: Haemophilus parasuis (H. parasuis) can invade the body and cause systemic infection under stress
conditions. Marbofloxacin has been recommended for the treatment of swine infections. However, few studies have
investigated the PK/PD characteristics and PK/PD cutoff (COPD) of this drug against H. parasuis.
Results: MICs of marbofloxacin against 198 H. parasuis isolates were determined. The MIC50 and MIC90 were 2 and
8 mg/L, respectively. An in vitro dynamic PK/PD model was established to study the PK/PD relationship of marbofloxacin
against H. parasuis. The PK/PD surrogate markers Cmax/MIC, Cmax/MPC (the maximum concentration divided by MIC or
mutant prevention concentration (MPC)) and AUC24h/MIC, AUC24h/MPC (the area under the curve during the first 24 h
divided by MIC or MPC) simulated the antimicrobial effect of marbofloxacin successfully with the R2 of 0.9928 and 0.9911,
respectively. The target values of 3-log10-unit and 4-log10-unit reduction for AUC24h/MPC were 33 and 42, while the same
efficacy for AUC24h/MIC were 88 and 110. The COPD deduced from Monte Carlo simulation (MCS) for marbofloxacin
against H. parasuis was 0.5 mg/L. The recommended dose of marbofloxacin against H. parasuis with MIC≤ 2 mg/L was
16 mg/kg body weight (BW).
Conclusions: The PK/PD surrogate markers AUC24h/MIC, Cmax/MIC and AUC24h/MPC, Cmax/MPC properly described the
effects of marbofloxacin. Marbofloxacin can achieve the best efficacy at dosage of 16 mg/kg BW for strains with MIC
values≤ 2 mg/L, therefore, it is obligatory to know the sensitivity of the pathogen and to treat animals as early as
possible. The very first COPD provide fundamental data for marbofloxacin breakpoint determination.
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Background
Haemophilus parasuis (H. parasuis) is not only a com-
mon inhabitant bacterium of the upper respiratory tract
in swine but also an etiological agent of Glässer’s disease
characterized by arthritis, fibrinous polyserositis, and
meningitis [1]. H. parasuis can invade the body and
cause systemic infection under stress conditions, for ex-
ample, weaning, transporting, and decaying of maternal
immunity [2]. It can also co-infect with immunosuppres-
sive agents, i.e., porcine reproductive and respiratory
syndrome (PRRS) virus [2]. Strains of serovars 1, 5, 10,
12, 13, and 14 were highly virulent and caused death or
morbidity [3]. Among all of the serovars, serovars 5 and
4 are the most prevalent among isolates reported in
China [4], Denmark [5], Germany [3], and the United
States [6, 7].
H. parasuis infection is often treated with sulfanila-
mide, quinolones, or cephalosporins. However, some iso-
lates have developed resistance to these drugs [8]. The
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most important factor for the emergence and dissemin-
ation of resistance is the exposure, especially exposure
to sub-optimal drug concentrations [9]. The PK/PD
modelling which helps determine exposure-response re-
lationships is of great importance in determining anti-
microbial regimens administered to animals to attain
appropriate effects [10]. The Fluoroquinolones and
Cephalosporin of 3th and 4th generations that have been
re-licensed in Europe took into account not only the
classical paradigm of concentration-dependent dosage
but also the PK/PD indices best descried the effects and
minimized the emergence of resistances, such as
AUC24h/MIC, Cmax/MIC, the percent time that drug
concentrations were above the minimum inhibitory con-
centration (%T >MIC), AUC24h/MPC, the percent time
that marbofloxacin concentrations were above the mu-
tant prevention concentration (%T >MPC) or the mu-
tant selection window (TMSW). Marbofloxacin, a third
generation fluoroquinolone, has been developed solely
for veterinary treatment. It acts as a concentration-
dependent bactericidal agent against Gram-negative and
gram-positive bacteria [11]. Marbofloxacin has been rec-
ommended by the European Committee and China for
the treatment of swine infections with a dosage regimen
of 2 mg/kg/24 h BW for three to five days. However, the
PK/PD relationship of it against H. parasuis is sparse.
Susceptibility breakpoint for an antimicrobial may assist
in determining whether an antibacterial is potentially
useful in the treatment of a bacterial infection. Knowing
whether an antimicrobial is useful will promote prudent
use of antimicrobial drugs. Breakpoints should be set
prior to an antibacterial being used clinically or at the time
of an approved use. Its setting requires integration of
knowledge of the wild-type distribution of MICs, the PK/
PD relationship of an antibacterial, and clinical outcomes
of infections when the antibacterial is used [12]. Veterinary
susceptibility breakpoints are developed by the Clinical
and Laboratory Standards Institute (CLSI) subcommittee
on Veterinary Antimicrobial Susceptibility Testing (VAST)
[13]. At this time, however, no veterinary specific clinical
breakpoints of marbofloxacin have been established for
swine disease caused by H. parasuis.
COPD determined by MCS that considers pharmacoki-
netic variation in target animals and PK/PD indices
assisted in the defining of susceptibility breakpoints from
the perspective of exposure–response relationship [14].
This method has also been used by regulatory agencies
such as the U.S. FDA and the European Medicines
Agency (EMA), or relevant specialized groups such as
CLSI-AST and the European Committee on Antimicro-
bial Susceptibility Testing (EUCAST), in defining the
susceptibility breakpoints [15].
The purpose of this investigation was to study the PK/
PD relationship of marbofloxacin against H. parasuis,
derive a COPD of marbofloxacin and recommend a rea-
sonable dosage regimen. MICs of marbofloxacin against
those isolates were determined. An in vitro PK/PD infec-
tion model was used to investigate marbofloxacin effects
against H. parasuis strain of serotype 5, which is a highly
virulent serotype and is one of the most prevalent sero-
types in China. Pharmacokinetics of marbofloxacin in
swine obtained from a previous study and PK/PD indices
were integrated into a Monte Carlo simulation to derive




All husbandry practices and experimental operations
were performed with full consideration of animal wel-
fare. Research ethical approval was granted by the South
China Agriculture University Animal ethics committee
(2014–03).
Strains and antibiotic
A strain of H. parasuis, serovar 5 (V5), kindly provided by
Professor Ming Liao, College of Veterinary Medicine, South
China Agricultural University, Guangzhou, Guangdong
Province, China was used in the present study. V5 was
marbofloxacin susceptible with a MIC of 0.015 mg/L.
The other 189 isolates of H. parasuis were collected
from swine in south China regions between August
2010 and July 2011. Serotypes of these isolates are not
known. Tryptone soya agar (TSA) and Tryptone soya
broth (Oxoid Ltd., Basingstoke, Hampshire, UK), supple-
mented with 2 % beta-Nicotinamide adenine dinucleotide
trihydrate (NAD) (Qingdao Hope Bio-Technology Co.,
Ltd., Shandong, China) and 5 % new-born calf serum
(Guangzhou Ruite Bio-tec Co., Ltd., Guangdong, China),
were used to culture H. parasuis. Marbofloxacin was pur-
chased from Hebei Yuanzheng Pharmaceutical Company
(Hubei, China).
Susceptibility testing
Considering that there is no recommended testing
method by CLSI’s VAST Subcommittee for H. parasuis,
MICs were conducted in accordance with the CLSI
recommendations for Actinobacillus pleuropneumoniae.
[16] (Wakiec et al., 2008) The Actinobacillus pleurop-
neumoniae ATCC 27090 strain was used for quality con-
trol purpose. MIC50 and MIC90 were defined in the
present study as the lowest concentration that inhibited
the growth of 50 % and 90 % of isolates tested, respect-
ively. The mutant prevention concentration (MPC) value
was determined according to previous reports [17, 18].
Single bacteria colony from 24 h growth on TSA was
grown for 12 h in TSB broth, then concentrated through
centrifugation and re-suspended it in TSB to a final
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concentration of ~ 3 × 1010 CFU/mL. An aliquot of 500
μL samples was plated onto TSA plates containing vari-
ous concentrations of marbofloxacin, and then incubated
for 24 h, 36 h and 48 h for re-growth. MPCpr was de-
fined as the lowest drug concentration that inhibits
growth. A second measurement was performed using
linear drug concentration increment within 20 % per se-
quential increase. All the determinations were carried
out in triplicates.
In vitro PK/PD model
The in vitro one-compartment PK/PD infection model
equipment was constructed according to previously de-
scribed method with some improvements [19]. An
inverted 50 mL centrifuge tube with a cellulose ester
membrane (0.2-μm pore size) covering the top was
placed in the central compartment to prevent bacteria
from flowing out to the medium. A magnetic stir bar
was placed on the bottom of the central compartment
which mixed the broth and enabled the drug to fully
contact the bacteria. The flow rate was 0.171 mL/min to
simulate the half-life of marbofloxacin in swine as de-
scribed previously [20].
In vitro time kill curves of marbofloxacin
A 12 h culture of V5 at logarithmic phase was added to
the central compartment to reach a final concentration
of 107 colony forming unit (cfu)/mL. An incubation
period of 30 min was applied to adapt the bacteria to
the new environment. Different doses of marbofloxacin
or control (sterile normal saline) were administered into
the central compartment, and at the same time, the peri-
staltic pump was turned on. Samples were obtained at
time points of 0, 3, 6, 9, 12, and 24 h. 100 μL of the sam-
ples were diluted properly with sterile normal saline, ali-
quots of the last four diluted samples were dropped
onto the TSA plates and incubated at 37 °C for 24 h.
The limit of determination was 400 cfu/mL.
Pharmacokinetics and PK/PD analysis
The samples for marbofloxacin concentration determin-
ation were centrifuged at 8,000 rpm at 4°C for 10 min.
The supernatant was stored at −80 °C and analyzed using
High Performance Liquid Chromatography (HPLC), which
had been optimized by our laboratory [21] within 1 month.
All experiments were performed in duplicate on different
days. The PK data were analyzed using Phoenix WinNon-
lin 6.0 software (Pharsight Co. Ltd.).
As marbofloxacin is concentration dependent, the PK/
PD index of marbofloxacin was AUC24h/MIC and Cmax/
MIC [22]. The PK/PD indexes were calculated using the
pharmacokinetic data and MIC value in each dose of the
time–kill curve. The in vitro drug effect was quanti-
fied by changes in log10 cfu counts between 24 h and
0 h. Data were analysed using sigmoid Emax model
WINNONLIN software (version 6.1; Pharsight, CA,
USA) with the following equation:




Where E0 is the change in log10 cfu/mL after 24 h in-
cubation in the control sample, compared with the ini-
tial inoculum. Emax is the difference in effect between
the greatest amount of growth (as seen for the growth
control, E0) and the greatest amount of kill. Ce is the
AUC24h/MIC, Cmax/MIC or Cmax/MPC in the effect
compartment. EC50 is the AUC24h/MIC, Cmax/MIC or
Cmax/MPC value producing a 50 % reduction in bacterial
counts from the initial inoculum, and N is the Hill coef-
ficient that describes the steepness of the curve.
Monte Carlo analysis (MCS)
A 10,000-subject Monte Carlo simulation was conducted
using Crystal Ball Professional V7.2.2 software based on
a previous pharmacokinetic study of marbofloxacin in
pigs and PK/PD target indices obtained in this study.
AUC24h and Cmax were assumed to be log-normally dis-
tributed in the form of mean values and confidence in-
tervals. The COPD is the MIC at which the probability of
target attainment (PTA) equals to 90 %, which is the
most commonly used standard for susceptibility break-
points in other bacteria [12].
Dosage calculation
In order to deduce a more rational regimen, the general
formula was employed to estimate dosages for different




F  fu 24h
Where Dose is the optimal dose (mg/kg day), CL is
the body clearance (L/kg day), AUC/MIC is the break-
point marker for the desired effect, MIC90 is the MIC
inhibiting 90 % of strains (mg/L), F is the bioavailability,
and fu is the free drug fraction.
Results
MICs of marbofloxacin against H. parasuis were widely
distributed, ranging from 0.003 mg/L to 16 mg/L (Fig. 1).
A trimodal distribution was observed with peak value
observed at 0.003, 0.06, and 2 mg/L, respectively. The
MIC50 and MIC90 were 2 and 8 mg/L, respectively. The
MPC of strain V5 was 0.04 mg/L at different time end-
points (24, 36 and 48 h), which was about 2 ~ 3 times of
the MIC value (0.015 mg/L).
The pharmacokinetics of marbofloxacin in pigs was
well simulated by this model with the relative deviation
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below 7 %. Time killing curves were shown in Fig. 2.
The marbofloxacin inhibited H. parasuis moderately
when the AUC24h/MIC was less than 13.8. The bacteria
decreased rapidly within 12 h, but re-grew to 106 cfu/
mL at 24 h with the AUC24h/MIC of 46. When the
AUC24h/MIC was 55 and 73, H. parasuis could not be
detected at 12 h, however, re-growth was observed at 24
h. When AUC24h/MIC was 92 and 110, marbofloxacin
killed H. parasuis without regrowth in 24 h (4-log-unit
and 5-log-unit decrease, respectively). The relationship
between in vitro antimicrobial efficacy and PK/PD surro-
gate markers (AUC24h/MIC or Cmax/MIC) was described
using the sigmoid Emax model. Both of the PK/PD surro-
gate markers simulated the in vitro antimicrobial effect
of marbofloxacin successfully with the R2 of 0.9928 and
0.9911 respectively (Figs 3, 4). The estimated Log Emax,
Log E0, EC50, and slope were shown in Tables 1 and 2
respectively. The target values of 3-log10-unit and 4-
log10-unit decreases for Cmax/MIC were 6.5 and 8 while
for AUC24h/MIC were 88 and 110, respectively. The
same effects for surrogates Cmax/MPC and AUC24h/
MPC were 2.5, 3 and 33, 42 respectively. They also simu-
lated the in vitro antimicrobial effect of marbofloxacin
successfully with the R2 of 0.9928 and 0.9911 respectively.
As there are no PK data of marbofloxacin with a dose
of 2 mg/kg BW, data of 2.5 mg/kg BW were used for
MCS. In the simulation, with the PK/PD target AUC24h/
MIC of 88, PTA > 90 % could only be achieved for iso-
lates with MIC ≤ 0.125 mg/L (Fig. 5). For dosage regimen
of 8 mg/kg BW with a single dose administered by IM,
PTA > 90 % could be achieved for isolates with MIC ≤
0.5 mg/L (Fig. 5). The COPD for marbofloxacin against
H. parasuis was 0.5 mg/L. The recommended dose of
marbofloxacin for bactericidal effect against H. parasuis
was 16 mg/kg BW.
Discussion
Currently, a great deal of information is available on the
PK/PD relationship of fluoroquinolones. The parame-
ters Cmax/MIC and AUC24h/MIC correlate well with
therapeutic outcome. According to literature, AUC24h/
MIC of >125 h and Cmax/MIC of >10 was usually used
as a threshold for successful therapeutic outcome of
fluoroquinolones against gram negative bacteria [23].
Nevertheless, these thresholds may be different for
some fluoroquinolones. The greatest influence for the
differences was the immune status of the animal. Fur-
thermore, the PK/PD indices of the same drug against
different pathogens also vary. For example, the threshold of
AUC24h/MIC is 46 h for bactericidal action in an ex vivo
PK/PD study of marbofloxacin against Mannheimia hae-
molytica [24]; AUC24h/MIC ratios for no reduction, 3 log10
and 4 log10 reductions in bacterial count from the initial
inoculum count were 41.9, 59.5, and 68.0 h forM. haemoly-
tica and 48.6, 64.9, and 74.8 h for P. multocida in an ex
vivo PK/PD study of marbofloxacin [25]. So it is of great
importance to study the PK/PD indices of fluoroquinolones
individually. Data on the PK/PD indices of marbofloxacin
against H. parasuis are limited. In this study, PK/PD
Fig. 1 Minimum inhibitory concentrations of marbofloxacin against
199 isolates of H. parasuis
Fig. 2 Time–kill curve of marbofloxacin against H. parasuis in the in vitro PK/PD model
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surrogates (Cmax/MIC, AUC24h/MIC and Cmax/MPC,
AUC24h/MPC) simulated the bacterial reduction effects
very well. The AUC24h/MIC ratios for no reduction, 3
log10, and 4 log10 reductions in bacterial count were 50,
88, and 110 h, while the Cmax/MIC ratios for those effects
were 3.5, 6.5, and 8. The threshold value is higher than
those derived from ex vivo PK/PD model. For these com-
parisons, it should be noted that there are significant differ-
ences between dynamic in vitro and ex vivo conditions.
There is a continuous exposure to a fixed concentration of
Fig. 3 Sigmoid Emax model relationships between antibacterial effect [E, log10 (cfu/mL)] and Cmax/MIC of marbofloxacin in the in vitro PK/PD
model against H. parasuis with an inoculum size of 1 × 107 cfu/mL
Fig. 4 Sigmoid Emax model relationships between antibacterial effect [E, log10 (cfu/mL)] and AUC24h/MIC of marbofloxacin in the in vitro PK/PD
model against H. parasuis with an inoculum size of 1 × 107 cfu/mL
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the agent for a defined duration (e.g., 24 h) in an ex vivo
model, whereas a gradient of concentration in the dynamic
in vitromodel. The level of AUC24h/MPC (33 for 3 log10 re-
ductions) was higher than that (12.89 for bactericidal effect)
resulted from a tissue cage model of marbofloxacin against
Pasteurella multocida [26]. The greatest influence for the
differences might be the immune status of the animal. The
value of Cmax/MPC (2.5 for bactericidal effect) was almost
the same with that (Cmax/MPC> 2.2) of levofloxacin against
staphylococcus aureus in a hollow fiber PK/PD model [27].
Though, both the PK/PD surrogates derived from MIC and
MPC described the effect properly, PK/PD surrogates de-
rived from MPC has been proven to be superior for fluoro-
quinolones over the classic PK/PD indices based on MIC
for minimizing the emergence of resistances and preventing
therapeutic failure [27].
Susceptibility breakpoint setting requires knowledge of
the wild-type distribution of MICs, assessment of the
PK/PD indices, and study of the clinical outcome of in-
fections treated with the antibacterial. Monte Carlo
simulation shows great advantage in supporting deter-
mination of the susceptibility breakpoint using drug
exposure-effect relationship [14], which takes pharmaco-
kinetic variation and PK/PD indices into consideration.
For the simulation, as it had been proved that the effi-
cacy of a single dosing regimen was better than doses
administered every 24 h or 48 h of the same total
amount of marbofloxacin [26], the EMA recommended
dose regimen can be converted to 8 mg/kg BW with a
single dose. Though both AUC24h/MIC and Cmax/MIC
were PK/PD indices of fluoroquinolones, AUC24h is a
much more robust estimation than the one of a single
snapshot Cmax which depends on many factors such as
sampling schedule. Therefore the PK/PD target was de-
fined to be AUC24h/MIC with value of 88. The COPD of
marbofloxacin against H. parasuis was 0.5 mg/L under
one short dose of 8 mg/kg. This COPD value was equal
to the clinical breakpoints values and the PK/PD break-
points values of ciprofloxacin, moxifloxacin (0.5 mg/L),
ofloxacin (0.5 mg/L), and levofloxacin(1 mg/L) against
Haemophilus influenzae, another bacteria of Haemophilus
spp in human clinic use [28]. Unfortunately, the proposed
PK/PD cutoff would designate a large proportion of clin-
ical H. parasuis isolates as resistant to the marbofloxacin.
Swine infected by these isolates will probably have a low
likelihood of responding to therapy.
Clinical dosage regimens of antimicrobial agents are
traditionally determined by relating the PK of drugs in
healthy animals and the in vitro antibacterial activity or
the treatment outcome at given dosages in disease
models or in clinical trials involving limited strains. Al-
though these parameters can predict the potency of the
drug against pathogens to a certain extent, they actually
Table 1 PK/PD analysis of marbofloxacin with the parameter of
Cmax/MIC and Cmax/MPC against H. parasuis
Parameter (units) Value
Log Emax (cfu/mL) 6.8




Cmax/MIC (bacteria elimination) 8
Cmax/MPC (bactericidal) 2.5
Cmax/MPC (bacteria elimination) 3
Slope (N) 3.2
Note: E0 is the change in log10 cfu/mL after 24 h incubation in the control
sample compared with the initial inoculum. Emax is the difference in effect
between the greatest amount of growth (as seen for the growth control, E0)
and the greatest amount of kill. EC50 is the Cmax/MIC value producing a 50 %
reduction in bacterial counts from the initial inoculum, and N is the Hill
coefficient that describes the steepness of the dose–response curve
Table 2 PK/PD analysis of marbofloxacin with the parameter of
AUC24h/MIC and AUC24h/MPC against H. parasuis
Parameter (units) Value
Log Emax (cfu/mL) 6.8




AUC24h/MIC (bacteria elimination) 110
AUC24h/MPC (bactericidal) 33
AUC24h/MPC (bacteria elimination) 42
Slope (N) 3.2
Note: E0 is the change in log10 cfu/mL after 24 h incubation in the control
sample compared with the initial inoculum. Emax is the difference in effect
between the greatest amount of growth (as seen for the growth control, E0)
and the greatest amount of kill. EC50 is the AUC24h/MIC value producing a
50 % reduction in bacterial counts from the initial inoculum, and N is the Hill
coefficient that describes the steepness of the dose–response curve
Fig. 5 The Probability of target attainment (PTA) for different
marbofloxacin doses against isolates of H. parasuis with different MICs
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don’t provide information on the time course of anti-
microbial activity. Fortunately, the relationship of PK/PD
parameters and the clinical outcomes have been fully in-
vestigated and applied in optimizing drug regimens; the
regimens based on PK/PD results were usually calcu-
lated by the general formula [23]. In the calculation, the
PK/PD threshold, the PK parameters and MIC distribu-
tion were taken into accounted. As the fu of marbofloxa-
cin in swine plasma was sparse, the value in dog plasma
was used to substitute that. According to our best know-
ledge, the CL of marbofloxacin was 0.065 ± 0.011 L/kgh;
the bioavailability was 90 % ± 28 %; the protein binding
rate was 21.81 % ± 6.26 %; MIC50 is 2 mg/L [20, 29].
When the MIC90 was used to calculate the dose, we
found the result (64 mg/kg BW) was too high to apply
in clinical usage. Considering the MICs of some H. parasuis
isolated in China are very high, they may exhibit resistance
to marbofloxacin that cannot be treated by marbofloxacin.
MIC50 was used in the calculation. the result showed that a
dose of 16 mg/kg would be able to achieve bactericidal ef-
fect. This dose is much higher than the recommended dose
(2 mg/kg for 3 to 5 days), and higher than that (10 mg/kg)
[30] recommended for bovine respiratory disease based on
the theoretical principle of single-injection, short-acting
antibiotic (SISAAB), which has been primarily developed
and applied to fluoroquinolones used in human medicine
[31]. It seems that even a dose as high as 16 mg/kg BW
cannot cure all the H. parasuis infection in China. It is
well-known that fluoroquinolones can lead to cross-
resistance among different members of the class [32], since
they are widely used to treat respiratory diseases. It is better
to check the susceptibility of pathogens before drug admin-
istration, as resistance determinants may transfer to human
pathogenic bacteria, resulting in the failure of antibiotics in
treatment of bacterial infection.
However, there are some limitations in our study. First,
the PK/PD indices targets were based on the drug con-
centration at infection sites, whist drug concentration of
plasma were used for MCS. Though, the penetration of
marbofloxacin is good and the tissue concentration is
similar to that in blood [26], concentration at infection
sites should be simulated in future trials. A second limi-
tation is that the recommended regimen is useful in just
the regions of China as MIC probability distribution of a
determined pathogen may vary between countries and
regions and even time. Finally, our proposed COPD will
need to be validated in the clinical outcome.
Conclusions
In summary, this study established an in vitro dynamic
PK/PD modelling of marbofloxacin against H. parasuis.
The target PK/PD values of marbofloxacin for 3-log10-
unit and 4-log10-unit decreases effects were Cmax/MIC
of 6.5 and 8, Cmax/MPC of 2.5 and 3, AUC24h/MIC of 88
and 110 or AUC24h/MPC of 33 and 42 respectively. The
very first marbofloxacin COPD (0.5 mg/L) derived based
on MCS was of great utility in marbofloxacin suscepti-
bility test and dosing design. Marbofloxacin can have the
best efficacy at dosage of 16 mg/kg BW for strains with
MIC values ≤ 2 mg/L, therefore, it is obligatory to know
the sensitivity of the pathogen and to treat animals as
early as possible.
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